Insider · CIK 0001290976
Arthur S Kirsch
director
Files at AVIR (Atea Pharmaceuticals, Inc.), LQDA (Liquidia Corp), EVMN (Evommune, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +26,700 | $0.00 | $0 | 26,700 | Jun 23, 2026 |
| Jun 18, 2026 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,700 | $0.00 | $0 | 37,700 | Jun 23, 2026 |
| Nov 5, 2025 | EVMN Evommune, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,960 | $0.00 | $0 | 37,960 | Nov 7, 2025 |
| Jun 17, 2025 | LQDA Liquidia Corp | AGrant or award Common Stock | +18,396 | $0.00 | $0 | 40,755 | Jun 20, 2025 |
| Feb 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +164,800 | $0.00 | $0 | 164,800 | Feb 24, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.